Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study.
L
autoimmune diseases
cancer
mistletoe
safety analysis
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
28
2
2019
pubmed:
28
2
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Viscum album L (VA, mistletoe) extracts are commonly used in integrative oncology. Here the clinical safety profile of additional VA-treatments to standard care in cancer patients with preexisting autoimmune diseases was analyzed. In this observational cohort study medical data and recorded adverse events (AEs) of treated patients were retrieved from the Network Oncology registry and a safety analysis was performed. A total of 106 patients (median age 63 years) treated with add-on VA-extracts were analyzed. Most frequent autoimmune diseases were Hashimoto's thyroiditis (27%), psoriasis (19%), and ulcerative colitis (15%). Seventeen patients (16%) experienced VA-related AEs, but neither long-term side effects nor VA-therapy discontinuations were recorded. In a subgroup of 30 patients receiving long-term VA-therapy no exacerbations or flares of underlying autoimmune diseases were recorded. Additionally, a significant halving of overall AE-rates was observed during VA-treatment periods (p= 0.019). Our findings suggest that add-on VA-therapy in cancer patients with preexisting autoimmune diseases as Hashimoto's thyroiditis, psoriasis, ulcerative colitis, Grave's disease, and some rheumatic diseases is safe. No higher rates of VA-associated AEs were observed and the overall AE-rates were significantly lowered in VA-therapy periods. However, results should be interpreted with caution in light of the study's observational character.
Sections du résumé
BACKGROUND
Viscum album L (VA, mistletoe) extracts are commonly used in integrative oncology. Here the clinical safety profile of additional VA-treatments to standard care in cancer patients with preexisting autoimmune diseases was analyzed.
METHODS
In this observational cohort study medical data and recorded adverse events (AEs) of treated patients were retrieved from the Network Oncology registry and a safety analysis was performed.
RESULTS
A total of 106 patients (median age 63 years) treated with add-on VA-extracts were analyzed. Most frequent autoimmune diseases were Hashimoto's thyroiditis (27%), psoriasis (19%), and ulcerative colitis (15%). Seventeen patients (16%) experienced VA-related AEs, but neither long-term side effects nor VA-therapy discontinuations were recorded. In a subgroup of 30 patients receiving long-term VA-therapy no exacerbations or flares of underlying autoimmune diseases were recorded. Additionally, a significant halving of overall AE-rates was observed during VA-treatment periods (p= 0.019).
CONCLUSIONS
Our findings suggest that add-on VA-therapy in cancer patients with preexisting autoimmune diseases as Hashimoto's thyroiditis, psoriasis, ulcerative colitis, Grave's disease, and some rheumatic diseases is safe. No higher rates of VA-associated AEs were observed and the overall AE-rates were significantly lowered in VA-therapy periods. However, results should be interpreted with caution in light of the study's observational character.
Identifiants
pubmed: 30808274
doi: 10.1177/1534735419832367
pmc: PMC6432670
doi:
Substances chimiques
Plant Extracts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735419832367Références
Forsch Komplementmed. 2007 Feb;14(1):9-17
pubmed: 17341882
Blood Cells Mol Dis. 2001 Jul-Aug;27(4):750-6
pubmed: 11778659
PLoS One. 2016 Jul 29;11(7):e0160221
pubmed: 27472273
Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628
pubmed: 29623110
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
Cancer Immunol Immunother. 2016 Jul;65(7):813-9
pubmed: 26910314
Int Arch Allergy Immunol. 2016;171(3-4):166-179
pubmed: 27960170
Autoimmun Rev. 2018 Jun;17(6):610-616
pubmed: 29631064
Ann Oncol. 2012 Apr;23(4):927-33
pubmed: 21810731
Evid Based Complement Alternat Med. 2014;2014:236310
pubmed: 24955100
Cancer Res. 2009 Aug 15;69(16):6482-9
pubmed: 19654312
BMC Complement Altern Med. 2017 Dec 13;17(1):534
pubmed: 29237435
Eur J Clin Pharmacol. 2008 Oct;64(10):999-1004
pubmed: 18604529
Autoimmun Rev. 2017 Oct;16(10):1049-1057
pubmed: 28778707
Phytomedicine. 2017 Dec 1;36:54-58
pubmed: 29157828
Int J Mol Sci. 2018 Jan 26;19(2):
pubmed: 29373557
Forsch Komplementmed. 2013;20(5):353-60
pubmed: 24200825
Arzneimittelforschung. 2006 Jun;56(6A):508-15
pubmed: 16927532
Arzneimittelforschung. 2004;54(8):456-66
pubmed: 15460213
Evid Based Complement Alternat Med. 2014;2014:724258
pubmed: 24672577
Explore (NY). 2012 Sep-Oct;8(5):277-81
pubmed: 22938746
Eur J Hum Genet. 2009 Feb;17(2):236-43
pubmed: 18781189
Anticancer Res. 2008 May-Jun;28(3B):1893-7
pubmed: 18630477
J Autoimmun. 2007 Feb;28(1):1-6
pubmed: 17261360
BMC Complement Altern Med. 2011 Aug 28;11:72
pubmed: 21871125
Integr Cancer Ther. 2015 Mar;14(2):140-8
pubmed: 25552476
Anticancer Res. 2008 Jan-Feb;28(1B):523-7
pubmed: 18383896
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003297
pubmed: 18425885
BMC Complement Altern Med. 2011 Nov 24;11:116
pubmed: 22114899
Toxicol Pathol. 2017 Jan;45(1):172-189
pubmed: 27895264
Rheum Dis Clin North Am. 2017 Feb;43(1):65-78
pubmed: 27890174
Patient Prefer Adherence. 2018 Mar 16;12:375-397
pubmed: 29588576
Evid Based Complement Alternat Med. 2012;2012:219402
pubmed: 21747894
Curr Opin Gastroenterol. 2016 Jul;32(4):274-81
pubmed: 27152873
Evid Based Complement Alternat Med. 2016;2016:4628287
pubmed: 27239209
Phytomedicine. 2011 Jan 15;18(2-3):151-7
pubmed: 20724129